SCHEMBL3252007

SCHEMBL3252007

COc1ccccc1S(=O)(=O)Nc1ccc(Cl)cc1Cc1ccccc1Cl

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
NPC1 O15118 1/20 0.58
WDR5 P61964 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 1/20 0.49
ACLY P53396 2/20 0.48
SLC22A12 Q96S37 1/20 0.47
PTGES2 Q9H7Z7 3/20 0.46
CCR4 P51679 1/20 0.45
ALPL P05186 1/20 0.44
MYC P01106 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4863945 0.93 TSHR (0.60) TSHRNPC1WDR5MEN1KMT2A
SCHEMBL4865757 0.90 TSHR (0.57) TSHRNPC1WDR5MEN1KMT2A
SCHEMBL3251138 0.84 GAA (0.47) TSHRNPC1MEN1KMT2ASMN1; SMN2
SCHEMBL27908886 0.83 TSHR (0.69) TSHRNPC1WDR5MEN1KMT2A
SCHEMBL3247467 0.82 LMNA (0.58) KMT2ACASP1SMN1; SMN2HSD17B10ALDH1A1
SCHEMBL3247458 0.80 KEAP1 (0.58) PTGES2
SCHEMBL3256105 0.79 ALDH1A1 (0.65) TSHRNPC1MEN1KMT2ASMN1; SMN2
SCHEMBL22005134 0.78 NPC1 (0.66) TSHRNPC1WDR5MEN1KMT2A
SCHEMBL3250123 0.75 MAPK1 (0.60) TSHRMEN1KMT2ACASP1CASP7
SCHEMBL3255588 0.74 TSHR (0.46) TSHRMEN1KMT2AHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
EP-1776347-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Sanofi-Aventis (FR) 2007-04-25 EP disclosed
WO-2006024779-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 TSHR 29/4885NPC1 3528/4885WDR5 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.